Premium
An 8.5‐kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regeneration
Author(s) -
Orfali Wayel,
Nicholson Robert N.,
Guiot MarieChristine,
Peterson Alan C.,
Snipes G. Jackson
Publication year - 2005
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.20425
Subject(s) - wallerian degeneration , biology , transgene , remyelination , axon , myelin , schwann cell , microbiology and biotechnology , neuroscience , gene , genetics , central nervous system
Altered expression of the PMP22 gene causes Charcot‐Marie‐Tooth disease type 1A (CMT1A) and hereditary neuropathy with liability to pressure palsies (HNPP). We have examined the promoter activity of 8.5 kb upstream of the first coding exon of the rat peripheral myelin protein‐22 (r Pmp22 ) gene in transgenic mice. We found that the −8.5 kb r Pmp22 /chloramphenicol acetyl transferase (CAT)/β‐galactosidase ( lacZ ) construct directs reporter gene expression in a weakly developmental and tissue‐specific pattern, consistent with the expression pattern of the endogenous Pmp22 gene. The −8.5 kb r Pmp22 /CAT/ lacZ transgene responds to loss of axonal signals during Wallerian degeneration but unlike the endogenous Pmp22 gene, the transgene fails to respond to axonal signals during nerve regeneration after a sciatic nerve crush injury. In conclusion, the function of the −8.5 kb r Pmp22 /CAT/ lacZ transgene suggests that there are separable regulatory elements in the r Pmp22 gene that respond differently to axonal signals received by Schwann cells during nerve development, and during remyelination. © 2005 Wiley‐Liss, Inc.